CRVS
Price
$10.21Alerts
Change
+$0.04 (+0.39%)
Updated
Nov 18, 04:59 PM (EDT)
Capitalization
886.63M
126 days until earnings call
Intraday BUY SELL Signals
VOR
Price
$17.83Alerts
Change
-$0.35 (-1.93%)
Updated
Nov 18 closing price
Capitalization
1.18B
127 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRVS vs VOR

CRVS vs VOR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CRVS vs. VOR commentary
Nov 19, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRVS is a Hold and VOR is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CRVS with price predictions
Nov 17, 2026

Aroon Indicator for CRVS shows an upward move is likely

CRVS's Aroon Indicator triggered a bullish signal on November 17, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 195 similar instances where the Aroon Indicator showed a similar pattern. In 174 of the 195 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CRVS's RSI Oscillator exited the oversold zone, 32 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on CRVS as a result. In 75 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.

The Moving Average Convergence Divergence (MACD) for CRVS just turned positive on October 20, 2026. Looking at past instances where CRVS's MACD turned positive, the stock continued to rise in 32 of 41 cases over the following month. The odds of a continued upward trend are 78%.

Following a +1.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRVS advanced for three days, in 200 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 56 cases where CRVS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

CRVS moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

CRVS broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.935) is normal, around the industry mean (3.592). P/E Ratio (-16.469) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).

The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. CRVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 74 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for VOR with price predictions
Nov 17, 2026

VOR saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for VOR moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 51 similar instances where the indicator exited the overbought zone. In 48 of the 51 cases the stock moved lower. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VOR as a result. In 83 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for VOR turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 43 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

VOR moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VOR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

Bullish Trend Analysis

Following a +7.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where VOR advanced for three days, in 182 of 218 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

VOR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 107 of 121 cases where VOR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-5.875) is normal, around the industry mean (3.592). P/E Ratio (0.110) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).

The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. VOR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VOR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
CRVS: Fundamental Ratings
CRVS
OUTLOOK RATING
1..100
21
VALUATION
overvalued / fair valued / undervalued
1..100
11
Undervalued
PROFIT vs RISK RATING
1..100
74
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
56
P/E GROWTH RATING
1..100
19
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CRVSVOR
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 8 days ago
81%
Bullish Trend 10 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
88%
COMPARISON
Comparison
Nov 19, 2026
Stock price -- (CRVS: $10.17 vs. VOR: $18.18)
Brand notoriety: CRVS and VOR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRVS: 83% vs. VOR: 83%
Market capitalization -- CRVS: $886.63M vs. VOR: $1.18B
CRVS [@Biotechnology] is valued at $886.63M. VOR’s [@Biotechnology] market capitalization is $1.18B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRVS’s FA Score shows that 2 FA rating(s) are green while VOR’s FA Score has 2 green FA rating(s).

  • CRVS’s FA Score: 2 green, 3 red.
  • VOR’s FA Score: 2 green, 3 red.
According to our system of comparison, VOR is a better buy in the long-term than CRVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRVS’s TA Score shows that 5 TA indicator(s) are bullish while VOR’s TA Score has 3 bullish TA indicator(s).

  • CRVS’s TA Score: 5 bullish, 4 bearish.
  • VOR’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CRVS is a better buy in the short-term than VOR.

Price Growth

CRVS (@Biotechnology) experienced а -10.55% price change this week, while VOR (@Biotechnology) price change was -7.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.90%. For the same industry, the average monthly price growth was -10.19%, and the average quarterly price growth was -24.01%.

Reported Earning Dates

CRVS is expected to report earnings on Mar 24, 2027.

VOR is expected to report earnings on Mar 25, 2027.

Industries' Descriptions

@Biotechnology (-10.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

CRVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been closely correlated with ACRS. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRVS jumps, then ACRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
-4.06%
ACRS - CRVS
68%
Closely correlated
-6.24%
RZLT - CRVS
42%
Loosely correlated
+12.15%
IMNM - CRVS
37%
Loosely correlated
-2.44%
AMLX - CRVS
36%
Loosely correlated
-1.01%
VOR - CRVS
36%
Loosely correlated
-4.16%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VKTX26.880.08
+0.30%
Viking Therapeutics
TORO3.63-0.06
-1.63%
Toro Corp
EFX180.30-9.20
-4.85%
Equifax
TE1.33-0.16
-10.74%
T1 Energy Inc.
DOGZ0.26-0.10
-28.65%
Dogness (International) Corp